Clinical Trial Update: Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating sequential testosterone and enzalutamide for castration-resistant metastatic prostate cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration Resistant Metastatic Prostate Cancer

Drugs mentioned

• TESTOSTERONE (testosterone)
• Xtandi (enzalutamide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Castration Resistant Metastatic Prostate Cancer | Phase 2 | Status: RECRUITING